Cancer Specialty
Conference Coverage
- ASCO 2024
- AACR 2024
- ASCO GI 2024
- ASH 2023
- SABCS 2023
- MOASC
- ASCO 2023

Advertisement

X (Twitter) LinkedIn Facebook

X (Twitter) LinkedIn Facebook

Cancer Specialty
Conference Coverage
- ASCO 2024
- AACR 2024
- ASCO GI 2024
- ASH 2023
- SABCS 2023
- MOASC
- ASCO 2023

Home » AML-ALL US Focus 2023, La Jolla, July 7-8 2023 – Version 2

Bladder

AML-ALL US Focus 2023, La Jolla, July 7-8 2023 – Version 2

By adminSeptember 19, 2023No Comments1 Min Read

Twitter LinkedIn Facebook Email

Share

Twitter LinkedIn Facebook Email

an AML-ALL US Focus Meeting 2023 video

Advertisement Single Below Content

Advertisement Single Below Content

Advertisement Single Below Content

Follow on X (Twitter) Follow on LinkedIn Follow on Facebook Follow on Google News

Share. Twitter LinkedIn Facebook Email

Related Posts

Monty Pal, MD – Top 5 ASCO 2024 Kidney & Bladder Cancer Must See Presentations

Bladder 1 Min Read

FDA Approves New Bladder Cancer Therapy: A Look at Anktiva Nogapendekin Alfa Inbakicept-pmln

Bladder 4 Mins Read

Enfortumab Vedotin & Bladder Cancer: Thomas Powles, MD ESMO 2023

Bladder 2 Mins Read

Advertisement Sidebar

Recent Posts

NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024
FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma SLIDES
SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer
VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC

Connect With Us on Social

Facebook
Twitter
LinkedIn

Above Footer

Above Footer

Above Footer

X (Twitter) LinkedIn Facebook

© 2024 Copyright Protected Medicus Networks, Inc..

Type above and press Enter to search. Press Esc to cancel.